UNSPSC 51401701: Captodiame or captodiamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H29NS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H93K9455DD, chemically known as 2-((p-(butylthio)-alpha-phenylbenzyl)thio)-n,n-dimethylethylamine but generally known as captodiame, which bears US NIH Compound Identifier 10240. Captodiame most often comes in base and hydrochloride forms. European Medicines Agency schedules Captodiame in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06080MIG.

UNSPSC 51401701 Captodiame or captodiamine is a Commodity code that in recent state and local procurement shows minimal direct activity under its nominal chemical classification; the three recent opportunities tagged to this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and OTC products — none of which are captodiame or captodiamine specifically. The code appears to reflect a tagging mismatch rather than active procurement of the chemical itself. State and local issuing bodies—including county health departments, state health and human services agencies, and multistate cooperative purchasing alliances—are the primary buyers when pharmaceutical and OTC products are solicited, though the recent sample shows no concentration among repeat buyers under this specific code.

The geographic spread of recent activity spans Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a procurement that extends to participating jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems (1,900 units of naloxone and 800 safe drug deactivation systems annually, IFB due July 26, 2023), the Texas Health and Human Services Commission's RFI HHS0017013 for direct-to-manufacturer prescription capabilities (posted April 3, 2026, as a preliminary market-intelligence solicitation), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with awards effective July 1, 2026). The code shows little relevant recent activity tied to captodiame or captodiamine as a discrete procurement category; business development professionals should verify the actual chemical or product scope of any opportunity tagged to this code before pursuing.